Warwick researchers develop new vehicle for drug release

Published: 1-Feb-2011
Drug Delivery Research & Development Pharmaceutical

Plankton inspires creation of ‘stealth’ armour for slow release microscopic drug vehicles

Researchers at the University of Warwick in the UK have devised a simple way of giving drug-bearing polymer vesicles (microscopic polymer-based sacs of liquid) their own ‘armoured protection’ after being inspired by the ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour.

The scientists have been able to decorate these hollow structures with a variety of nanoparticles, opening a new strategy in the design of vehicles for drug release, for example by giving the vesicle ‘stealth’ capabilities which can avoid the body’s defences while releasing the drug.

Advances in polymerisation have boosted the creation of vesicles made from polymer molecules. Such vesicles have special chemical and physical properties, which make them potential drug delivery vehicles.

The University of Warwick team believed that more strength and tailored properties could be given to the vesicles if they could add an additional layer of colloidal ‘armour’ made from a variety of nanoparticles.

Lead researcher, Associate Professor Stefan Bon, said: ‘We took our inspiration from nature, in how it adds protection and mechanical strength in certain classes of cells and organisms. In addition to the mechanical strength provided by the cytoskeleton of the cell, plants, fungi, certain bacteria have an additional cell wall as outermost boundary.

‘Organisms that particularly attracted our interest were those with a cell wall composed of an armour of colloidal objects – for instance bacteria coated with S-layer proteins, or phytoplankton, such as the coccolithophorids, which have their own CaCO3-based nano-patterned colloidal armour.’

The Warwick researchers hit on a simple and effective method of adding different types of extra armour to the polymer-based vesicles. One example was a packed layer of microscopic polystyrene balls. Because the polystyrene balls had a crystalline-like ordered structure, the researchers could design a vesicle with an additional and precise permeable reinforced barrier for drug release.

The researchers used the same technique to add a gelatine-like polymer to provide ‘stealth’ armour to shield vesicles from unwanted attention from the body’s immune system while it slowly released its drug treatment.

This particular coating (a poly((ethyl acrylate)-co-(methacrylic acid)) hydrogel) absorbs so much surrounding water into its outer structure that it may be able to fool the body’s defence mechanism into believing it is in fact just water.

See more

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

Read more
This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs

Trending Articles

  1. Echo MS+ integration enhances high-throughput mass spectrometry SCIEX expands compatibility with the ZenoTOF 8600 system to deliver greater sensitivity and automation capabilities
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy
  3. CARBOGEN AMCIS and Celonic unveil integrated ADC development platform at World ADC London 2026 The strategic alliance combines biologics and highly potent payload capabilities to streamline ADC development and manufacturing

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

AI might find the molecule, but delivery decides whether it becomes a medicine

As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?
Subscribe now